Today, we take our first in-depth look at Rubius Therapeutics which has developed a new class of cellular therapies called Red Cell Therapeutics.
The company's pipeline has several candidates in development and Rubius recently addressed its current funding needs.
A full investment analysis follows in the paragraphs below.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
[Smile]